|
|
Scribes in healthcare settings free up physician time to talk to patients. |
|
NY Times: Without much fanfare or planning, scribes have entered the scene in hundreds of clinics and emergency rooms. Physicians who use them say they feel liberated from the constant note-taking that modern electronic health records systems demand. Indeed, many of those doctors say that scribes have helped restore joy in the practice of medicine, which has been transformed — for good and for bad — by digital record-keeping.
|
|
|
New device informs treatment of sleep apnea. |
|
EurekAlert: Implantation of a sleep apnea device called Inspire® Upper Airway Stimulation (UAS) therapy can lead to significant improvements for patients with obstructive sleep apnea (OSA), according to a study published today in the New England Journal of Medicine. After one year, patients using the device had an approximately 70 percent reduction in sleep apnea severity, as well as significant reductions in daytime sleepiness.
|
|
Potential rewrite of human research guidelines will facilitate database studies. |
|
Institute of Medicine: To first determine if research activities fall within the scope of the Common Rule, the report recommends that HHS define “human subjects research” as a systematic investigation designed to develop or contribute to generalizable knowledge that involves direct interaction or intervention with a living individual or that involves obtaining identifiable private information about an individual. Only research that fits this definition should be subject to IRB procedures and the Common Rule.
|
|
ZS Pharma announces positive results from extended treatment results of hyperkalemia drug. |
|
ZS Pharma: ZS003 Phase 3 Top-Line Results. Top-line results from the Extended Treatment Phase showed that ZS-9 was able to maintain a statistically significant reduction in serum potassium relative to placebo in patients over 12 days of once-daily dosing. .............................. • The trial met the Extended Treatment Phase endpoint at the 5g and 10g doses compared with placebo (P-values of 0.0075, and <0.0001, respectively). ......................................... • ZS-9 was well-tolerated at all doses tested. Overall adverse event and GI adverse event rates and severities were comparable between the placebo and ZS-9 treated patients.
|
|
Portable retinal scanner developed for early detection of eye disease. |
|
OSA: A new optical device puts the power to detect eye disease in the palm of a hand. The tool—about the size of a hand-held video camera—scans a patient’s entire retina in seconds and could aid primary care physicians in the early detection of a host of retinal diseases including diabetic retinopathy, glaucoma and macular degeneration.
|
|
|
|
|
<< Start < Prev 231 232 233 234 235 236 237 238 239 240 Next > End >>
|
|
Page 232 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
